March 2019: We have reviewed the evidence and made new recommendations on mediastinal lymph node assessment, brain imaging, prophylactic cranial irradiation, radical radiotherapy and operable stage IIIA disease. These recommendations are marked .
We have also made some changes without an evidence review:
Recommendations 1.3.2, 1.3.10, 1.3.14, 1.3.15, 1.4.13, 1.4.16 and 1.4.38 were updated to fit with the recommendations made in the 2019 evidence review, and to reflect current best practice.
Recommendations 1.3.5, 1.3.11, 1.3.18 were updated to reflect current terminology.
Recommendation 1.3.17 has had 'fibreoptic' removed, because bronchoscopy can be fibreoptic, video or hybrid.
Recommendation 1.3.30 has had a reference to the Welsh Government and Department of Health removed, as the optimal lung cancer pathway now covers this area.
Recommendation 1.3.34 was updated to reflect current practice and to be in line with the NICE quality standard on lung cancer.
These recommendations are marked [2005, amended 2019] or [2011, amended 2019].
Recommendations marked  or  last had an evidence review in 2005 or 2011. In some cases minor changes have been made to the wording to bring the language and style up to date, without changing the meaning.